Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US
Mylan Partnership Bears Fruit
Executive Summary
Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.
You may also be interested in...
Biocon Partners With Voluntis On Digital Therapeutics For Diabetics
The global collaboration agreement pairs Biocon’s insulins with Voluntis’s Insulia, the first digital therapeutic with regulatory clearance for insulin-dependent type 2 diabetes patients. Biocon further reveals plans for a complete digital therapeutics portfolio for patients
Keeping Track: US FDA Approvals Include Novel Agents Zepzelca And Uplizna, Biosimilar Nyvepria, Follow-On Semglee
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Mylan And Biocon’s Semglee Insulin Glargine Approved In US
Mylan and Biocon have received FDA approval for their Semglee insulin glargine product, with a path to market seemingly clear after Mylan emerged victorious in several recent patent-litigation challenges. Meanwhile, the firm continues to strive towards an interchangeability designation that would make it a much more valuable opportunity.
Need a specific report? 1000+ reports available
Buy Reports